251 related articles for article (PubMed ID: 10801241)
1. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
2. Differential impairment of triazolam and zolpidem clearance by ritonavir.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
J Acquir Immune Defic Syndr; 2000 Jun; 24(2):129-36. PubMed ID: 10935688
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Greenblatt DJ; von Moltke LL; Harmatz JS; Counihan M; Graf JA; Durol AL; Mertzanis P; Duan SX; Wright CE; Shader RI
Clin Pharmacol Ther; 1998 Sep; 64(3):278-85. PubMed ID: 9757151
[TBL] [Abstract][Full Text] [Related]
5. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
6. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
[TBL] [Abstract][Full Text] [Related]
7. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
[TBL] [Abstract][Full Text] [Related]
8. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
[TBL] [Abstract][Full Text] [Related]
10. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
[TBL] [Abstract][Full Text] [Related]
11. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
[TBL] [Abstract][Full Text] [Related]
12. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
13. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.
Greenblatt DJ; von Moltke LL; Daily JP; Harmatz JS; Shader RI
J Clin Psychopharmacol; 1999 Aug; 19(4):293-6. PubMed ID: 10440454
[No Abstract] [Full Text] [Related]
14. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
15. Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
Patki KC; Greenblatt DJ; von Moltke LL
J Pharm Pharmacol; 2004 Aug; 56(8):963-6. PubMed ID: 15285839
[TBL] [Abstract][Full Text] [Related]
16. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
17. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
Flentge CA; Randolph JT; Huang PP; Klein LL; Marsh KC; Harlan JE; Kempf DJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5444-8. PubMed ID: 19679477
[TBL] [Abstract][Full Text] [Related]
19. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
von Moltke LL; Greenblatt DJ; Harmatz JS; Duan SX; Harrel LM; Cotreau-Bibbo MM; Pritchard GA; Wright CE; Shader RI
J Pharmacol Exp Ther; 1996 Feb; 276(2):370-9. PubMed ID: 8632299
[TBL] [Abstract][Full Text] [Related]
20. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
Weemhoff JL; von Moltke LL; Richert C; Hesse LM; Harmatz JS; Greenblatt DJ
J Pharm Pharmacol; 2003 Mar; 55(3):381-6. PubMed ID: 12724045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
